Jaguar Health, Inc.: Business Overview, Financials & Competitive Analysis
Jaguar Health, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Plant-based therapeutics company with promising crofelemer program across multiple indications, but severely capital-constrained with significant near-term execution and dilution risks. Jaguar faces headwinds as a commercial-stage biotech with a market cap of only ~$3.7M and declining stock price momentum (currently $0.85 vs. 52-week high of $15.75). However, the company.
What is Jaguar Health, Inc.'s industry? Jaguar Health, Inc. (jaguar.health) operates in Biotechnology/Pharmaceuticals - Gastrointestinal Therapeutics. AskCyborg classifies Jaguar Health, Inc. under Biotechnology/Pharmaceuticals - Gastrointestinal Therapeutics in its company registry.
Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointest...
Cyborg Score thesis
Plant-based therapeutics company with promising crofelemer program across multiple indications, but severely capital-constrained...
Read the full analyst-debate transcript →Get the Latest Jaguar Health, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeJaguar Health, Inc. Overview
Pro stress-test →Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel. The company operates through two segments—Human Health and Animal Health—with approved products and multiple clinical programs advancing through development.
Strategic Profile
Pro stress-test →The lead product Mytesi (crofelemer) is an oral plant-based prescription drug made from sustainable sources and is FDA-approved for treatment of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and generates revenue. The company is expanding crofelemer across multiple indications including cancer-related diarrhea, rare diseases, and animal health applications while maintaining a focus on plant-based, non-opioid therapeutic solutions.
Competitive Landscape
Pro stress-test →Jaguar competes in the GI therapeutics and rare disease space with other biotech companies pursuing anti-diarrheal and GI disorder treatments. Key differentiator is the plant-based, sustainable sourcing strategy and dual Human/Animal Health segments. Competitors include other antidiarrheal developers and broader GI therapeutics companies, though Jaguar's botanical approach and crofelemer's unique mechanism provide some competitive insulation.
Industry Context
Jaguar Health, Inc. operates in Biotechnology/Pharmaceuticals - Gastrointestinal Therapeutics.
Key facts
Founded: 2013 · Headquarters: San Francisco, California · Employees: 49 · Market cap: $3.7M